QA: KALA BIO Inc in us_pharma/2023

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001479419_2024_KALA_BIO_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning Missing logo subcommand.report {}
info NetIncome node detected by revenue/expenses heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'OperatingIncomeLoss'}
info Ambiguous roles for statement input.sec.calculation_linkbase.expand_agg {'statement': 'operations', 'valid_roles': {'00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS': 15, '00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Calc 2)': 1}}

Graph

Absolute values for 0001479419, KALA BIO Inc

  xvar xval
0 AssetsCurrent 52,870,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 753,000
3 remainder_Assets 2,326,000
4 LiabilitiesCurrent 8,346,000
5 LiabilitiesNoncurrent 40,099,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 20,567,000
9 ResearchAndDevelopmentExpense 18,586,000
10 remainder_Expenses 510,000
11 remainder_Revenues 0
12 remainder_NetIncome 0
13 remainder_ComprehensiveNetIncome -2,536,000
  yvar yval
0 Assets 55,949,000
1 Liabilities 48,445,000
2 Expenses 39,663,000
3 Revenues 0
4 StockholdersEquity 7,504,000
5 NetIncome -39,663,000
6 ComprehensiveNetIncome -40,931,000
7 BaseVar 73,296,500
8 EconomicCapitalRatiobeforeLimitedLiability -0.471
9 EconomicCapitalRatio 1.39

Edgar->Model Mapping

Feature Distribution

Change over Time